a Shantani Proteome Analytics Pvt. Ltd ., Pune , Maharashtra , India.
Expert Opin Drug Discov. 2016 Oct;11(10):1017-25. doi: 10.1080/17460441.2016.1227316. Epub 2016 Aug 31.
Drug discovery efforts across the globe are chasing new drug targets and novel mechanisms of action. To support the identification of novel mechanisms of action, phenotype-based drug screening has significantly increased over the last decade. Along with the rise in phenotypic screening, methods and technologies that can help to identify drug targets of phenotypically screened 'hits' have also evolved significantly.
This article provides an overview of successful examples, limitations and advances in small-molecule target identification methodologies. Primarily, the methods are described, where small-molecules without derivatization are used as test-molecules for identifying their direct binding protein partners, the targets, in detail. A brief discussion of other affinity chromatography coupled mass-spectrometry based target identification methods are also presented for comparative appreciation of label-free methods.
Label-free methods do not require (a) extensive structure activity analysis of phenotypically screened 'hits' and (b) preparation of tool compounds or target capturing probes for target identification. These methods are significantly shortening the time required for the identification and the downstream validation of targets and hence are gaining popularity as the method of choice for target identification.
全球范围内的药物发现工作都在追寻新的药物靶点和新的作用机制。为了支持新型作用机制的鉴定,基于表型的药物筛选在过去十年中显著增加。随着表型筛选的兴起,有助于鉴定表型筛选“命中”的药物靶点的方法和技术也有了显著的发展。
本文概述了小分子靶标鉴定方法的成功案例、局限性和进展。主要描述了在详细鉴定其直接结合蛋白伴侣(即靶标)时,不进行衍生化的小分子作为测试分子的方法。还简要讨论了其他基于亲和色谱耦联质谱的靶标鉴定方法,以便对无标记方法进行比较评价。
无标记方法不需要:(a) 对表型筛选“命中”物进行广泛的结构活性分析,和 (b) 为靶标鉴定制备工具化合物或靶捕捉探针。这些方法大大缩短了靶标鉴定和下游验证所需的时间,因此作为靶标鉴定的首选方法越来越受欢迎。